Background
Chloroquine and hydroxy chloroquine (quinolones) are used primarily by rheumatologists for rheumatoid arthritis and systemic lupus erythematosus, and by dermatologists for cutaneous lupus. They bind to melanin and interact with nucleic acids.
Although irreversible retinopathy has been described with the use of these drugs, this has occurred at total doses in excess of those currently recommended. The literaturel,2 and contemporary practice3,4 favour the use of low dose hydroxy chloroquine which confers minimal risk, or the unrelated antimalarial mepacrine (which has negligible ocular toxicitys). Chloroquine base should only be considered if these agents have failed, as there are inadequate data to advise on a safe maximum dose. In six case series with a total of some 1500 patients treated with hydroxychloroquine, only one case of retinopathy with visual loss was observed. [6] [7] [8] [9] [10] [11] In the largest single series one patient out of 1207 developed retinopathy after 7 years.u Where doses of hydroxy chloroquine were kept below 6.5 mg / kg / day lean body weight, no cases of toxicity were found in 973 patients followed.9,13 However, 2 cases of retinopathy have been reported when the drug was used for > 6 years.14
Clinical features

Reversible
• Corneal epithelial changes (verticillata): these do not often cause symptoms,
• Loss of normal foveal reflex,
Irreversible
• Fine granular appearance to macula.
• 'Bull's eye' maculopathy -only this sign is associated with impaired visual acuity and central visual field disturbance. 
IS
Recommendations for good practice in rheumatology and dermatology clinics
Baseline assessment
• Establish renal and liver function.
• Ask about visual impairment (which is not corrected by spectacles).
• Record near visual acuity of each eye (with spectacles where appropriate) using a test type* or the reading chart in Fig. 1 .
If no abnormality is detected, treatment with hydroxychloroquine can be commenced. 
Maximum daily dosage recommendations
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Fig.t. Test types.
If visual impairment is present an assessment by an optician is advised. Any relevant abnormality detected would be referred to an opthalmologist in the usual way.
Annual evaluation
Patients should be monitored yearly, enquiring about visual symptomatology, rechecking acuity and assessing for blurred vision using the reading chart. 
Referral to the ophthalmologist
Referral to the ophthalmologist is appropriate if any patient:
• Has visual impairment or eye disease detected at baseline assessment. It should be noted that in elderly patients there is often coincidental ocular morbidity from cataract, glaucoma and age-related maculopathy.
• Develops change in acuity or blurred vision (as assessed by reading chart) whilst on treatment.
Patients should be warned to stop treatment and seek advice from the prescribing doctor.
• Although quinolones are not officially licensed for children, the drug (often chloroquine for convenient dosage) is used in specialist units particularly in the management of juvenile chronic arthritis and systemic lupus erythematosus. These children are already attending the ophthalmologist for slit-lamp examination to check for the development of uveitis.
Examination by the ophthalmologist
Examination should include assessment of:
• distance and near acuity;
• colour vision;
• visual field -use of a red pin and red Amsler grid is helpful;
• examination of the cornea by slit-lamp;
• the retina.
Examination may need to be extended according to signs and symptoms.
Subsequent examinations should be at the discretion of the ophthalmologist, but indefinite follow-up is not likely to be required. For the patient who ultimately requires long-term treatment (> 5 years) an individual arrangement should be agreed with the local ophthalmologist.
